Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform
MRVI•MRVI•MRVI•MRVI•Maravai LifeSciences highlighted a turnaround from COVID-driven revenue to a streamlined growth platform, citing cost cuts above $65 million.
It said the company is focusing on mRNA, gene editing, and cell and gene therapy tools through TriLink and Cygnus, with priorities in commercial execution, operational excellence, and R&D focus.
The company reported 1H 2026 revenue of $117.3 million, up 24%, with adjusted gross margin of 62.5%.
It posted 1H adjusted EBITDA of $29 million, returning to positive levels, and cited a $50 million improvement versus 1H 2025.
Maravai also pointed to base revenue growth of 9% year over year, excluding $14.3 million of COVID GMP CleanCap revenue in Q1.
